The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals.

导出 OA

翻译打印收藏纠错

第一作者： Elliot A,Philips

第一单位： Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York 10016.

作者： Elliot A,Philips ^[1] ; Antonio,Garcia-España ^[2] ; Anna S,Tocheva ^[3] ; Ian M,Ahearn ^[4] ; Kieran R,Adam ^[3] ; Ruimin,Pan ^[1] ; Adam,Mor ^[5] ; Xiang-Peng,Kong ^[6]

作者单位： Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York 10016. ^[1] Research Unit, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43005 Tarragona, Spain. ^[2] Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032. ^[3] Perlmutter Cancer Center, New York University School of Medicine, New York, New York 10016. ^[4] Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032 am5121@cumc.columbia.edu. ^[5] Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York 10016 xiangpeng.kong@nyulangone.org. ^[6]

关键词 PD-L2 T-cell biology glycoprotein structure immune checkpoint immune receptors/ligands immunotherapy programmed cell death protein 1 (PD-1)programmed death ligand 1 (PD-L1)protein evolution protein structure